Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | Evaluating the role of fruiquintinib in patients with refractory mCRC

Cathy Eng, MD, Vanderbilt-Ingram Cancer Center, Nashville, TN, discusses the impact of the approval of fruiquintinib, a VEGF inhibitor, in patients with refractory metastatic colorectal cancer (mCRC). Findings from the FRESCO (NCT02314819) and FRESCO-2 (NCT04322539) trials, which assessed fruiquintinib in patients from China and the rest of the world respectively. In the FRESCO-2 trial, patients who have progressed on trifluridine–tipiracil or regorafenib were recruited, and the primary endpoint of overall survival was met. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.